The drug is the only medicine of its kind proven to help patients with lupus nephritis regain full kidney response, the ...
AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...
With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...
The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...
The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...
Merck has kicked off construction of a new $3 billion facility at its sprawling manufacturing campus in Elkton, Virginia. | ...
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...
Zacks Investment Research on MSN
Carvana (CVNA) Outperforms Broader Market: What You Need to Know
Carvana (CVNA) closed the most recent trading day at $337.60, moving +1.14% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 1.07%. Elsewhere, the ...
Genentech, a member of Roche (RHHBY), announced that the FDA has approved Gazyva for the treatment of adult patients with active lupus nephritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback